# OnCo record nct03899155 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03899155/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03899155", "NCT03899155" ;
  schema:name "Pan Tumor Rollover Study"@en ;
  schema:description "A phase 2 trial of Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Capecitabine and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03899155/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03899155> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2019-08-09" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/exelixis/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/clovis-oncology/> .